Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies
Georgios Tsakonas, Luigi De Petris, Simon Ekman · Cancer Treatment Reviews · 2017
Cited by 47 works. doi:10.1016/j.ctrv.2017.02.004
Authors
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials
- Epidermal growth factor receptor mutations in lung cancer
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer